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During somatic reprogramming, Yamanaka’s pioneer
factors regulate a complex sequence of molecular
events leading to the activation of a network of plurip-
otency factors, ultimately resulting in the acquisition
and maintenance of a pluripotent state. Here, we
show that, contrary to the pluripotency factors
studied so far, overexpression of Mybl2 inhibits so-
matic reprogramming. Our results demonstrate that
Mybl2 levels arecrucial to thedynamicsof the reprog-
ramming process. Mybl2 overexpression changes
chromatin conformation, affecting the accessibility
of pioneer factors to the chromatin and promoting
accessibility for early immediate response genes
known to be reprogramming blockers. These
changes in the chromatin landscape ultimately lead
to a deregulation of key genes that are important for
the mesenchymal-to-epithelial transition. This work
defines Mybl2 level as a gatekeeper for the initiation
of reprogramming, providing further insights into
the tight regulation and required coordination of mo-
lecular events that are necessary for changes in cell
fate identity during the reprogramming process.
INTRODUCTION
Somatic reprogramming can be achieved through overexpres-
sion of the exogenous factors Oct4, Sox2, Klf4, and Myc
(OSKM), first described by Takahashi and Yamanaka (Takahashi
and Yamanaka, 2006). Since then, several reports have provided
detailed descriptions of the molecular dynamics of the reprog-
ramming process (Buganim et al., 2012; Hansson et al., 2012;
Li et al., 2010; O’Malley et al., 2013; Polo et al., 2012). Reprog-
ramming occurs in an organized way, with rapid genome-wide
transcriptional changes during the first days induced by OSKM
overexpression.1496 Cell Reports 24, 1496–1511, August 7, 2018 ª 2018 The Author
This is an open access article under the CC BY license (http://creativeDespite the recent increase in knowledge about factors that
enhance reprogramming such as Nanog (Theunissen et al.,
2011), Lin28 (Viswanathan et al., 2008), and chromatin remodel-
ers (Onder et al., 2012), and specific barriers that contribute to
lower reprogramming efficiency such as H3K9 methylation
(Chen et al., 2013) and upregulation of p53 and p21 (Banito
and Gil, 2010; Mario´n et al., 2009), the specific contribution of
each endogenous pluripotency factor to the reprogramming pro-
cess remains unknown. Elucidating the individual contributions
of pluripotency factors and epigenetic remodelers to the reprog-
ramming process is crucial to improve reprogramming efficiency
and to produce clinical grade induced pluripotent stem cells
(iPSCs) for their use in regenerative medicine.
Among the genes that are upregulated during reprogramming
is that encoding the transcription factor Mybl2. Despite its gen-
eral role in the regulation of proliferation (Musa et al., 2017) and
genome stability throughout the animal kingdom (Ahlbory
et al., 2005; Fung et al., 2002; Garcı´a and Frampton, 2006;
Manak et al., 2002; Shepard et al., 2005; Tarasov et al., 2008),
Mybl2 has been proposed to have a function as a pluripotency
gene. Mybl2 expression is between 1,000- and 10,000-fold
higher in embryonic stem cells (ESCs), iPSCs, and trophoecto-
derm stem cells than in somatic cells (Tarasov et al., 2008;
Benchetrit et al., 2015) and is downregulated during embryogen-
esis (Sitzmann et al., 1996). Similar to Oct4 or Sox2 knockout
phenotypes, mice lacking Mybl2 fail to develop past the blasto-
cyst stage as a result of impaired proliferation of the inner cell
mass (Tanaka et al., 1999). Moreover, it has been recently
demonstrated that Mybl2 is a chromatin-bound partner for
Oct4, Sox2, and Nanog in ESCs (Rafiee et al., 2016). Taken
together, this compelling evidence suggests that Mybl2 forms
part of a pluripotency network. In agreement with this, Mybl2
RNA levels increase gradually from day 5 of reprogramming,
which is even earlier than those encoding other pluripotency fac-
tors such asNanog (O’Malley et al., 2013; Polo et al., 2012). How
Mybl2 levels affect the reprogramming process and its exact role
during reprogramming remain unknown, however.
Here, we demonstrate that correct Mybl2 levels are critical for
reprogramming because both its deletion and overexpressions.
commons.org/licenses/by/4.0/).
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Figure 1. Mybl2 Deletion Inhibits Somatic
Reprogramming
(A) Mybl2F/D or Mybl2+/D were nucleofected with a
plasmid that encoded Cre-IRES-EGFP. GFP+ MEFs
were sorted, replated, and then transduced with
OSKM lentivirus. After 14 days, the MEFs were
stained for alkaline phosphatase activity.
(B) Mybl2F/D:Cre-ERT2+/ and Mybl2F/D:Cre-ERT2+/
MEFs were treated with 500 nm 4-OHT for 24 hr and
then cultured for a further 96 hr before being trans-
duced with OSKM lentiviral particles at MOI 2 or MOI
20. The MEFs were cultured for 12 days before being
stained for alkaline phosphatase activity. Colonies
with alkaline phosphatase activity are displayed in
red.Mybl2F/D orMybl2+/D were transduced with dox-
inducible Cre-ZsGreen lentiviral particles (MOI 10)
together with OSKM lacking loxP sites (OSKM-NL)
(MOI 2) to avoid its excision after dox addition. In the
case of the day 2 condition, the cells were trans-
duced with Cre-ZsGreen virus 2 days before infection
with OSKM-NL. Dox was added at different times
during the reprogramming process (days 1, 0, 3,
and 6) and then tested for pluripotency by scoring
ZsGreen+ colonies under the microscope and by
alkaline phosphatase staining at day 10.
(C) Plates showing positive AP staining (red) at day 10.
(D) Graph representing the ZsGreen+ colony counts.
n = 3 biological replicates. Error bars represent SEMs.
***p < 0.001 by unpaired two-tailed t test.
See also Figure S1.impair the reprogramming process. It is surprising that exoge-
nous expression of the reprogramming factors (OSK) is not suf-
ficient to upregulate the pluripotency program in the presence of
high levels of Mybl2. Overexpression of Mybl2 during the early
stages of the reprogramming process disturbs the chromatin
landscape and the accessibility of OSK to specific chromatin re-
gions affecting the dynamics of themolecular events required for
reprogramming to occur.
RESULTS
Mybl2D/D MEFs Are Unable to Reprogram
Given the role of Mybl2 in proliferation and senescence, we
sought to study whether reprogramming would be possible in
its absence. For this purpose, Mybl2 floxed allele was deleted
using a Cre-recombinase-GFP system in Mybl2F/D, using
Mybl2+/Dmouse embryonic fibroblasts (MEFs) as a control (Gar-
cı´a et al., 2005). The GFP+ MEFs were subsequently transduced
with STEMCCA (Sommer et al., 2009, 2010) (OSKM) lentiviral
particles to initiate reprogramming, and after 14 days the cells
were stained for alkaline phosphatase (AP) activity. Fewer AP+
colonies were detected in the Mybl2D/D MEFs compared to
Mybl2+/D MEFs. To avoid stressing the MEFs by transfection
and cell sorting, this experiment was repeated using MEFs
from an Mybl2F/D:CreERT2 strain in which nuclear translocationCellof Cre-recombinase was induced by 4-hy-
droxy tamoxifen (4-OHT) treatment (Fig-
ure 1B). Loss of Mybl2 protein was
confirmed 96 hr after 4-OHT treatment.Mybl2+/D:Cre-ERT2+/ or Mybl2F/D:Cre-ERT2+/ MEFs were
treated for 24 hr with 4-OHT and cultured for 96 hr before replat-
ing and transducing with OSKM lentiviral particles. After 12 days,
the cells were stained for AP activity. A reduction in the total
number of AP+ colonies was observed in the 4-OHT-treated
Mybl2F/D:Cre-ERT2+/ compared to the Mybl2+/D:Cre-ERT2+/
MEFs (43 ± 23 versus 82 ± 16 colonies, respectively). A possible
explanation for the presence of AP colonies in the 4-OHT-treated
Mybl2F/D:Cre-ERT2+/ plate could be the inefficient deletion of
the floxed (F) allele; thus, all individual iPSC colonies obtained
from two different experiments (a total of 50 colonies) were iso-
lated and genotyped, confirming the presence of the Mybl2F
allele. The absence of the Mybl2D/D colonies isolated from
different experiments suggests that Mybl2 expression is
required for reprogramming to occur. We also determined
whether lack of Mybl2 expression was detrimental at a specific
time window of the reprogramming process. We infected
Mybl2F/D and Mybl2+/D MEFs with STEMCCA lentivirus lacking
loxP sites (OSKM-NL) together with a doxycycline (dox)-induc-
ible Cre-ZsGreen lentivirus (1 day before dox addition). The
addition of dox at different times would activate Cre expression,
leading to the deletion of theMybl2F allele (Figure S1D). We also
infected cells with OSKM-NL 2 days after dox addition (day 2)
to delete theMybl2F allele before the initiation of reprogramming.
We observed that dox addition at different days before, at theReports 24, 1496–1511, August 7, 2018 1497
same time, or after OSKM-NL infection (days 2, 0, 3, and 6,
respectively) was detrimental to the reprogramming process
(Figures 1C and 1D). Moreover, the few colonies observed on
the Mybl2F/D plates showed negative staining for ZsGreen,
thus indicating that these colonies came from MEFs in which
the deletion of the Mybl2F allele did not occur (Figure S1E).
Mybl2 Overexpression Impairs Reprogramming
Given the block in reprogramming observed in the absence of
Mybl2 expression, we next sought to determine whether Mybl2
overexpression would have a positive impact on reprogramming
efficiency, as described for other known pluripotency factors
such as Nanog (Theunissen et al., 2011). In this endeavor,
MEFs were transduced with OSKM + ZsGreen or OSKM +
Mybl2 lentiviral particles, and AP activity was assayed after
10 days. We unexpectedly found that there were visibly fewer
AP+ colonies when the Mybl2 lentiviral particles were included
(OSKM + Mybl2 115 ± 10 compared to 183 ± 23 colonies when
reprogramming with OSKM + ZsGreen viruses) (Figures S2A
and S2B).
To confirm that Mybl2 overexpression impairs reprogram-
ming, we designed a polycistronic lentiviral vector containing
Oct4, Sox2, Klf4, and Mybl2 (OSKB). Oct4-GFP MEFs were
transduced with OSKM, OSK, or OSKB lentiviruses at MOI 2,
and ESC-like colony formation, GFP signal, and AP activity
were assayed at day 14 (Figure 2A). As expected, considering
the importance of Myc in reprogramming efficiency, the number
of AP+ colonies was visibly lower in OSK-transduced MEFs
compared to OSKM-transduced MEFs (Figures 2B and 2C).
We were surprised that many fewer colonies were observed in
MEFs transduced with OSKB (Figures 2B–2D). We also took
advantage of the Oct4-GFP knockin MEFs and determined the
expression of GFP in the iPSC colonies generated (an indication
of cells that have switched on the endogenous Oct4 promoter)
(Lengner et al., 2007). The number of GFP+ colonies was highest
when reprogramming with OSKM (130 ± 29) compared to OSK
(54 ± 18) and OSKB (1 ± 0; Figures 2D and 2E). These striking re-
sults suggest that Mybl2 overexpression is detrimental to the
overall reprogramming process.
With the aim of forcing the reprogramming process, the num-
ber of viral particles was increased by 10-fold (MOI 20). An in-
crease in the number of colonies was observed with each of
the different lentiviruses used, but still the number of colonies
obtained when reprogramming was performed with OSKB lenti-
virus was much lower (Figure 2C). Similar to MOI 2, we observed
that OSKM and OSK were able to reprogram much more
efficiently and with a higher number of GFP+ colonies than
OSKB ( OSKM = 333 ± 124, OSK = 347 ± 118, OSKB = 62 ±
23; Figure 2D). When scoring for GFP+ colonies, there was a
higher number of GFP positive colonies when reprogramming
with OSKM (142 ± 45) compared to OSK (135 ± 39) and OSKB
(46 ± 20; Figure 2D).
Given that Oct4 is expressed at an early stage of reprogram-
ming, it could be possible that the colonies scored as GFP+
would be not fully mature iPSCs (Buganim et al., 2012). Thus,
we sought to confirm our results using another reporter trans-
gene, Nanog-GFP MEFs (Chambers et al., 2007). In these set-
tings, we observed a lower reprogramming efficiency in1498 Cell Reports 24, 1496–1511, August 7, 2018the Nanog-GFP MEFs compared to Oct4-GFP MEFs, with the
OSKM being the most efficient at reprogramming, while the
OSKB was barely able to reprogram at all (OSKM = 71 ± 5,
OSK = 30 ± 17, OSKB = 5 ± 2; Figure 2E). The number of
Nanog-GFP+ colonies was 38 ± 4, 18 ± 10, and 3 ± 2 when re-
programming with OSKM, OSK, or OSKB, respectively (Fig-
ure 2E). By increasing the number of lentiviral particles by
10-fold we were able to enhance the efficiency of reprogram-
ming, but OSKB reprogramming was still inefficient (Figure 2E).
The number of GFP+ colonies when reprogramming with
OSKM was slightly higher with OSKM and OSK compared to
OSKB (OSKM=27± 2, OSK=29± 15,OSKB=14± 7; Figure 2E).
Of note, the reprogramming cultures were left for more than
26 days to account for a slower timing of OSKB reprogramming,
but even 26 days after OSKB transduction there was no increase
in the number of colonies obtained (data not shown).
Moreover, we found that impairment of reprogramming when
Mybl2 is included in the reprogramming cocktail is not due
to MEFs entering cellular senescence, cell-cycle arrest, or
apoptosis, since cells were negative for the b-galactosidase (Fig-
ure 2F), did not undergo significant changes in the expression of
p21, p53, and p16 genes (Figures 2G and 2H), and displayed a
similar percentage of apoptotic nuclei by the terminal deoxynu-
cleotidyl transferase deoxyuridine triphosphate nick end labeling
(TUNEL) assay (Figures 2I–2K). Furthermore, to determine
whether the reduced reprogramming efficiency was mediated
by p53, we transduced p53/ MEFs with OSKM or OSKB lenti-
viral particles at MOI 2 or MOI 20 and measured AP activity at
day 14 (Figures S2C–S2F). The mean number of colonies when
p53/ MEFs were transduced with OSKB at MOI 2 remained
close to zero (Figure S2D). By increasing the number of viral par-
ticles by 10-fold (MOI 20), a large increase in the number of AP
colonies could be observed when p53/ MEFs were trans-
duced with OSKM (671 ± 35) but not in OSKB-transduced
p53/ MEFs (61 ± 23 AP colonies; Figure S2F).
The above results using different lentiviral vector approaches
and different pluripotent reporter MEFs suggest that inclusion
of Mybl2 in the reprogramming cocktail dramatically reduces
the efficiency of reprogramming, and that this is independent
of p53 and cannot be attributed to cell-cycle arrest, apoptosis,
or senescence.
CD44/CD54 Reprogramming Kinetics Are Blocked in
MEFs Transduced with Mybl2 and Yamanaka Factors
Next, we aimed to identify the precise time at which addition of
Mybl2 would affect the reprogramming process. For this pur-
pose, MEFs were transduced with OSKM, OSK, or OSKB lentivi-
ral particles and tracked throughout the reprogramming process
using flow cytometry to measure the expression of surface anti-
gens CD44 and CD54 (Icam1) (O’Malley et al., 2013) (see gating
strategy in Figure S3).
MEFs were tracked through reprogramming at days 6, 9, 12,
and 16 after being transduced with OSKM, OSK, or OSKB lenti-
viral particles at MOI 2. At days 6 and 9, only OSKM-MEFs con-
tained CD44/CD54+ cells (Figure 3A) as the OSK and OSKB
remained comparable to non-transducedMEFs. The percentage
of CD44/CD54+ cells rose further at days 12 and 16 for OSKM-
MEFs and OSK MEFs; however, the OSKB-transduced MEFs
Figure 2. Mybl2 Overexpression Inhibits Somatic Reprogramming
(A) Schematic representation of the experimental procedure. Oct4-GFP or Nanog-GFP MEFs were transduced with MOI 2 or MOI 20 OSKM, OSK, or OSKB
lentiviral particles and allowed to reprogram for 14 days before GFP+ colonies were counted. The cells were stained for alkaline phosphatase activity.
(legend continued on next page)
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displayed a significantly lower percentage comparable to non-
transduced MEFs (Figure 3A).
Analysis of the reprogramming kinetics in OSKM-, OSK-, or
OSKB- (MOI 20) transduced MEFs was performed and demon-
strated the presence of CD44/CD54+ from day 6 in OSKM-
MEFs (Figure 3B), while a small increase in the percentage of
CD44/CD54+ cells was observed in OSK at day 9 or in OSKB
MEFs. By day 12, the proportion of those cells had increased
in all three conditions (Figure 3B). Finally, at day 16, we observed
reprogramming in all three conditions; however, there was a
significantly lower percentage of CD44/CD54+ cells in the
OSKB- (5.27% ± 0.85%) compared to the OSKM- (13.6% ±
1.1%) or OSK- (14.6% ± 0.89%) transduced MEFs (Figure 3B).
These data corroborate the colony number data because it is
possible to reprogram with OSKB at MOI 20 but at a reduced
efficiency compared to OSKM and OSK reprogramming.
By measuring the expression of CD44 and CD54 at days 6, 9,
12, and 16 of reprogramming, we sought to determine the per-
centage of partially reprogrammed iPSCs (pre-iPSCs, CD44,
and CD54), as shown in Figure 3C. Using this approach, we
observed 10% of pre-iPSCs at days 9 and 12 in MOI 2 OSKM-
MEFs and determined an increase at these time points in
OSK-MEFs, while OSKB-MEFs were not able to progress to a
pre-iPSC stage and remained at a percentage that is compara-
ble to non-transduced MEFs (Figure 3C).
A similar patternwas observedwhen theMOI of the reprogram-
ming lentiviruses was increased to 20. Under these conditions,
analysis of the reprogramming kinetics revealed a larger percent-
age of pre-iPSCs by day 6 for OSKM MEFs (Figure 3D). The per-
centage of pre-iPSCs was lower in OSKB compared to OSKM at
all four time points, this percentage being significantly lower at
days 6, 9, and 12. To determine whether the increase in reprog-
rammingobservedatMOI20wascausedby thehigherexpression
of OSK factors, we decided to fine-tune the expression of Mybl2,
keeping the levels ofOSKconstant.By infecting thecellswithOSK
at MOI 1 and Mybl2-AmCyan or AmCyan control at MOI 1 or MOI
20, we could determine the percentage of iPSCs formed that are
Cherry+ (infected with OSK) and AmCyan+ (infected with either
Mybl2-AmCyan or AmCyan control). Our analysis revealed that in-
fectingMybl2-AmCyanateitherMOI 1orMOI20hadadetrimental
effect on reprogramming, and by day 16, virtually no CD44/
CD54+ cells were detected (Figure S4A).(B and C) Alkaline phosphatase staining (red) of Oct4-GFP MEFs at day 14 after
(D) Bar graph representing the number of ESC-like colonies based onmorphology
n = 3 biological replicates.
(E) Bar graph representing the number of ESC-like colonies based on morpholo
SEMs. n = 3 biological replicates. *p < 0.05, **p < 0.01.
(F) Oct4-GFP MEFs were transduced with OSKB or OSK lentiviral particles at MO
activity, a marker of senescent cells. Representative image from 203magnificatio
100% confluence for 10 days without passage. n = 2 biological replicates.
(G and H) Wild-type MEFs at day 3 during reprogramming using OSKM, OSK or O
p53 (right) was measured by qRT-PCR, normalized against the b2-microglobulin
biological replicates.
(I) Wild-type MEFs were transduced with OSKM, OSK, or OSKB at MOI 2 or MOI
TUNEL assay. Representative merged images at 403magnification from confoca
50 mm. Positive control, MEFs treated with DNase I; negative control, non-transd
(J and K). Quantification of apoptotic nuclei counts from each condition MOI 2 (J
See also Figure S2.
1500 Cell Reports 24, 1496–1511, August 7, 2018These results demonstrate that an alteration in the reprogram-
ming kinetics occurs when Mybl2 is included as one of the
reprogramming factors and suggest that the block in reprogram-
ming occurs at an early stage in the process.
Early and Late Pluripotency Genes Fail to Be
Upregulated during Reprogramming in the Presence of
Mybl2
We then decided to determine whether the changes observed in
the reprogramming efficiency and kinetics in OSKB-transduced
MEFs could be the result of Mybl2 affecting the expression of a
number of genes involved in pluripotency, cell proliferation, or
the mesenchymal-to-epithelial transition (MET). With this pur-
pose, expression of the genes was measured by qRT-PCR at
days 3, 6, and 9 during reprogramming with OSK or OSKB lenti-
viral particles at MOI 2 andMOI 20. We compared OSK to OSKB
because of their similar reprogramming kinetics caused by the
omission of theMyc gene. Expression was calculated as relative
to the normal mouse ESC expression for each gene, except
Thy1, which was set relative to MEF expression because their
expression is not detectable in ESCs.
In agreement with our findings on the lack of pre-iPSCs and
fully reprogrammed iPSCs, we found that the expression of
Nanog, Lin28a, andCbx7 (late pluripotencymarkers) was not up-
regulated when reprogramming with OSKB at MOI 2 compared
to OSK (Figure 3E). We also found that the expression of early
pluripotency markers such as Fgf4, Etv5, and Sall4was impaired
when reprogramming with the OSKB lentivirus at MOI 2. More-
over, in these settings we failed to detect the expression of
Cdh1, a gene that is normally upregulated during MET (Fig-
ure 3E). When we increased the number of lentiviral particles
used for the transduction by 10-fold, we were partially able to
rescue the reprogramming defect. Thus, the mRNA level of
most of the genes analyzed had increased expression at this
higher MOI, although still at lower expression levels when
compared to cells reprogrammed with the OSK virus (Figure 3F).
We also showed that the fold change inMybl2 expression levels
decreased in OSKB compared to OSK as reprogramming pro-
gressed, which is indicative of a higher Mybl2 expression in the
OSK sample during reprogramming (Figure S4B). Moreover, af-
ter excision of the OSKB viral genomic DNA by Cre expression,
we could see that iPSCs derived from OSKB MOI 20 showedtransduction with MOI 2 (B) or MOI 20 (C).
and the number of Oct4-GFP-expressing colonies. Error bars represent SEMs.
gy and the number of Nanog-GFP-expressing colonies. Error bars represent
I 2 or MOI 20. After 3 days the cells were fixed and stained for b-galactosidase
n inverted bright-field microscope. For positive control, MEFs were cultured at
SKB at MOI 2 (G) or MOI 20 (H). RNA expression of p21 (left), p16 (middle), and
housekeeping gene, and expressed relative to non-transduced MEFs. n = 3
20. After 3 days, MEFs were stained for genomic DNA fragmentation with the
l microscope show apoptotic nuclei (red) and DAPI (blue). Scale bar represents
uced MEFs.
) and MOI 20 (K). n = 2 biological replicates.
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Figure 3. Reprogramming Kinetics in MEFs with Mybl2 Overexpression
(A–D) MEFs were transduced with OSK, OSKM, or OSKB lentiviral particles at MOI 2 (A and C) or MOI 20 (B and D) and then cultured up to 16 days. At days 6, 9,
12, and 16, MEFs were stained with CD44-APC and CD54-PE-Cy7 antibodies, and reprogramming kinetics were analyzed by flow cytometry. Graphs represent
the percentage of CD44/CD54+ or of CD44/CD54 cells. Error bars represent SEMs. n = 3 biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001.
(legend continued on next page)
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similar mRNA expression levels of the pluripotent genes to ESCs
(Figure S4C).
Reprogramming Kinetics Are Affected in Transgenic
Reprogrammable MEFs when Mybl2 Is Overexpressed
It has been reported that several reprogramming systems,
including the STEMCCA vector that we used, have a short Klf4
form, missing the first nine amino acids of wild-type Klf4 (Chant-
zoura et al., 2015). To determine whether this could be the
reason for the lack of reprogramming observed when Mybl2
was overexpressed, we used a reprogramming system with
transgenic (Tg) MEFs carrying dox-inducible Yamanaka factors.
These reprogrammable c-Myc, Klf4, Oct4, and Sox2 (MKOS)
MEFs contain the four Yamanaka factors (with a full-length
Klf4) integrated into the genome under the control of a tetracy-
cline response element and an mOrange reporter of transgene
expression (Chantzoura et al., 2015). A total of 10% MKOS
MEFs was mixed with 90%wild-type (WT) MEFs and then trans-
duced with Mybl2-AmCyan or AmCyan lentiviral particles.
Reprogramming was initiated by the addition of dox, and reprog-
ramming kinetics analyzing the expression of CD44 and CD54
were measured at days 9, 12, and 16 (Figures 4A and S5).
The mean percentage of CD44/CD54+ cells when trans-
duced with Mybl2 lentiviral particles was lower at days 9 and
12 compared to the AmCyan control. Furthermore, a greater dif-
ference was observed at day 16, with the percentage of those
cells being significantly lower in Mybl2-transduced MEFs
(6.79% ± 4.43%) compared to the corresponding AmCyan con-
trol (47.17% ± 17.43%) or untransduced cells (58% ± 4.8%,
p = 0.02 and 0.002, respectively; Figure 4B). The percentage of
pre-iPSCs (CD44/CD54) at days 12 and 16 was quite variable
between experiments (Figure S6A), although at day 9,Mybl2 pre-
iPS cells displayed a lower percentage of CD44/CD54 surface
expression (1.08% ± 0.58%) when compared to the AmCyan
control (8.96% ± 1.19%; Figure 4C). These data confirm that
Mybl2 overexpression has a negative impact on the reprogram-
ming efficiency. As before, we corroborated that Mybl2 overex-
pression did not have an impact on apoptosis or senescence
during Tg MEF reprogramming by measuring the percentage
of apoptotic nuclei and the expression of senescence-associ-
ated genes 3 days after dox induction (Figures 4D and 4E).
Less Detrimental Effect of Mybl2 Overexpression after
Day 3 of Reprogramming
Having defined that Mybl2 has a negative impact on reprogram-
ming, we next investigated the effects of Mybl2 overexpression
at different time points of reprogramming. We transduced
MKOS MEFs with AmCyan control or Mybl2-AmCyan lentiviral
particles 3 days after the initiation of reprogramming (Figure S6B)
and assessed the kinetics of reprogramming by analyzing the
expression of CD44 and CD54 at days 9, 12, and 16, as indicated
in Figure 4F. At day 9, a small percentage of CD44/CD54+
iPSCs was observed in the non-transduced MKOS only(E and F) Wild-type MEFs were reprogrammed with OSKB or OSK lentiviral particl
was measured using qRT-PCR normalized against the b2-microglobulin gene an
One representative graph is shown; n = 3 biological replicates, each with 3 techn
See also Figures S3 and S4.
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MEFs displayed basal levels that were comparable to those of
non-induced MEFs (Figure 4G). However, we could observe
the appearance of partially reprogrammed CD44/CD54 cells
in both AmCyan (6.07% ± 3.37%) and Mybl2-AmCyan MEFs
(9.47% ± 4.27%) from day 9 (Figures 4H and S6C), unlike
when the lentiviral transduction was performed on day 1 of re-
programming (Figure 4C). A large increase in the percentage of
CD44/CD54+ cells was observed at day 12 in all three condi-
tions, being 32.83% ± 8.67% in the non-transduced, 27.07% ±
6.38% in the AmCyan-transduced, and 16.87% ± 1% in
the Mybl2-AmCyan-transduced MKOS MEFs, maintaining the
similar percentage until day 16 (Figure 4G). This represents a
clear improvement in the efficiency of reprogramming when
Mybl2 was overexpressed from day 3 in contrast to day1 of re-
programming (Figure 4B). When MEFs were transduced with
AmCyan control or Mybl2-AmCyan lentiviral particles at day 7
of reprogramming (Figure S6D), both AmCyan- and Mybl2-
AmCyan-transduced MEFs displayed a great reduction in iPSCs
formation (4% ± 1% and 8.4% ± 1%, respectively) compared to
the non-transduced MEFs (53% ± 9%) (Figure S6E). This indi-
cated that lentiviral infection at this time point was detrimental
to efficient reprogramming and hindered precise assessment
of the impact of Mybl2 overexpression. Nevertheless, the fact
that Mybl2-overexpressing cells were reprogrammed equally
well, or even slightly better, compared to AmCyan-expressing
control cells indicated that the overexpression of Mybl2 from
day 7 was not disadvantageous. In summary, these data clearly
indicate that overexpressing Mybl2 at early time points can have
a larger detrimental effect on reprogramming.
Mybl2 Overexpression on Transgenic Reprogrammable
MEFs Leads to a Less Accessible Chromatin
Conformation
In an attempt to precisely determine the mechanism underlying
the detrimental nature of Mybl2 overexpression, we assessed
the chromatin landscape by assay for transposase-accessible
chromatin using sequencing (ATAC-seq) 3 days after the initia-
tion of reprogramming. To do this, we transduced Tg reprogram-
mable MEFs with Mybl2-AmCyan or AmCyan control lentivirus
1 day before the initiation of reprogramming, and 3 days after
dox addition (day 3) we sorted double-positive (mOrange+
AmCyan+) cells undergoing reprogramming and transduced
with lentivirus. Finally, we used ATAC-seq (Buenrostro et al.,
2015) to determine the open regions of chromatin (Figure 5A).
For additional controls, we performed ATAC-seq in Tg reprog-
rammable MEFs at time zero and 4 days after Tg reprogram-
mable MEFs were transduced with Mybl2-AmCyan without
going through the reprogramming process (no dox addition) (Fig-
ure 5A). This analysis revealed differentially regulated regions
during reprogramming when Mybl2 was overexpressed (Fig-
ure 5B), with chromatin regions remaining closed when Mybl2
was overexpressed during reprogramming (black box at bottomes at MOI 2 (E) or MOI 20 (F). At days 3, 6, or 9, expression of the indicated gene
d then expressed relatively to WT ESCs expression or MEFs (Thy1 only).
ical replicates.
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Figure 4. Mybl2 Overexpression Inhibits Tg Reprogrammable MEFs
(A) Schematic representation of the experimental design.
(B and C) Reprogramming kinetics studies using CD44-APC and CD54-PE-Cy7 at days 9, 12, and 16. Bar graphs represent the percentage of cells in the CD44/
CD54+ (B) or the CD44/CD54 quadrant (C). n = 3. *p < 0.05, **p < 0.01.
(legend continued on next page)
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of Figure 5B) and chromatin regions remaining open (black box
at top of Figure 5B). Because Yamanaka factors can act as
pioneer factors (Knaupp et al., 2017; Soufi et al., 2012), we
decided to determine whether the overexpression of Mybl2
could be affecting their binding to chromatin. We found it inter-
esting that when ATAC-seq peaks were analyzed based on
Oct4, Sox2, Oct4-Sox2, and Klf4 motifs, we observed an overall
difference in Sox2 motifs when comparing control and Mybl2-
AmCyan-transduced MKOS MEFs (Figure 5C). When the anal-
ysis was done on the ATAC-seq peaks that were different
between both conditions (top 10% differentially open loci), a
clear difference with respect to Oct4-Sox2, Sox2, and Oct4 mo-
tifs was observed between control and Mybl2-AmCyan-trans-
duced MKOS (Figure 5D), suggesting that the overexpression
of Mybl2 affects the binding of Sox2 and Oct4 to specific chro-
matin regions. In all cases, Oct4 and Sox2 motifs were not
centered on the ATAC-seq peak, while Klf4 motifs were
centered. Moreover, the analysis of the enriched motifs for the
10% of the peaks showing higher open chromatin in AmCyan
control MKOS (black box at the bottom of Figure 5B) revealed
that these regions were enriched in Klf4, Sox2, and Oct4/Sox2/
Tcf./Nanog binding sites (Figure S7A). Conversely, the enriched
motif analysis for the 10% of the peaks showing higher open
chromatin levels in Mybl2-AmCyan MKOS (black box at the
top of Figure 5B) revealed that these regions were enriched in
AP1 sites (Fra1, Fosl2, and Jun-AP1 binding sites) (Figure S7B).
These data suggest a less accessible environment for the bind-
ing of the Yamanaka factors on chromatin as a consequence of
Mybl2 overexpression at this stage of the reprogramming.
Furthermore, we took a closer look at unique peaks to determine
whether Mybl2 MKOS would still display an enrichment in those
specific motifs relative to the AmCyan control. A total of 377
unique ATAC-seq peaks were present in Mybl2-AmCyan control
and 1,952 unique peaks were observed in the AmCyan corre-
sponding control (Figure 5E). This analysis revealed that the
unique peaks present in AmCyan preferentially displayed
Sox2, Klf4, and Oct4-Sox2-Tcf.-Nanog motifs (Figure 5F), while
AP1 motifs were enriched in those peaks that were uniquely
observed in Mybl2-AmCyan-transduced MKOS (Figure 5G).
Gene Ontology (GO) analysis of the genes associated with the
peaks that were uniquely observed in AmCyan-transduced
MKOS showed that the genes related to pluripotency were
among the top 10 classes (logP =9.438 comparedwithlogP =
1.648 for Mybl2-AmCyan specific peaks; Figure 5H). Consistent
with AP1motifs being enriched in the peaks uniquely observed in
Mybl2-AmCyan-transduced MKOS, the GO analysis revealed
the mitogen-activated protein kinase (MAPK) signaling pathway
as one of the top 10 enriched classes in Mybl2 MKOS (logP =
5.969 compared with logP = 0.76 for AmCyan-specific peaks;
Figure 5I).(D) Quantification of apoptotic nuclei counts at day 3 or reprogramming. n = 2 bi
(E) RNA expression of p21 (left), p16 (middle), and p53 (right) was measured by
expressed relative to non-transduced Tg reprogrammable MEFs (MKOS). n = 3
(F) Schematic representation of the experimental design.
(G and H) Graphs represent the percentage of CD44/CD54+ cells (G) at days 9, 1
replicates.
See also Figures S5 and S6.
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JunD chromatin immunoprecipitation sequencing (ChIP-seq) in
MEFs and during somatic reprogramming (Liu et al., 2015; Vier-
buchen et al., 2017), we observed that AP1 is binding in Mybl2-
specific ATAC peaks and shared peaks in WT MEFs and Klf4,
Sox2, Myc (KSM) MEFs (Figure S7C). Similarly, the intersection
of our ATAC-seq data with publicly available ChIP-seq data for
Oct4, Sox2, and Nanog in ESCs (Whyte et al., 2013), iPSCs,
and MEFs at day 3 of reprogramming (Knaupp et al., 2017) re-
vealed that MEFs at day 3 of reprogramming, iPSCs, and mouse
ESC (mESC) profiles (especially Sox2) were very similar to those
observed in the AmCyan ATAC-seq (Figures S7D and S7E).
The presence of AP1 motifs in the Mybl2-AmCyan- but not in
AmCyan-specific peaks also hints at the presence of active so-
matic enhancers, which are normally repressed during efficient
reprogramming (Chronis et al., 2017). Taken together, these
data demonstrate the detrimental effect of Mybl2 overexpres-
sion during somatic reprogramming, the biological consequence
of which is reflected by a less permissive chromatin landscape
for the binding of Yamanaka factors to their specific target re-
gions and a more permissive chromatin landscape for the bind-
ing of early immediate response genes that are known to be
reprogramming blockers (Li et al., 2017; Liu et al., 2015).
Mybl2 Overexpression during Reprogramming
Deregulates Mesenchymal-to-Epithelial Transition
These observations prompted us to determine whether the
changes in chromatin accessibility would lead to a distinct mo-
lecular signature and a specific transcriptome associated with
impaired reprogramming. Thus, we set out to perform global
gene expression profiling by RNA-seq comparing Tg reprogram-
mable MEFs transduced either with Mybl2-AmCyan or AmCyan
control 3 days after the initiation of reprogramming. With this
approach, we identified 350 differentially expressed genes (Fig-
ures 6A and 6B); these genes were mostly implicated in the
regulation of cell adhesion and extracellular matrix organization
GO categories such as Postn, Col3a1, Col5a2, Col11a1,
Adamts5, and Fmod (Figures 6C and S8A). Gene set enrichment
analysis (GSEA) revealed a negative correlation with the
expression of the genes that are part of the epithelial-to-mesen-
chymal transition pathway (MSigDB ref: M5930) (nominal [NOM]
p value <0.001, family-wise error rate [FWER] p value <0.001, as
shown in Figure 6D). Contrary to our expectations, these data
seem to suggest that Mybl2 expression is promoting a rapid
downregulation of themesenchymal genes, one of the first steps
for somatic reprogramming to occur. Nonetheless, the key
genes required for proper MET transition and establishment of
an epithelial fate were deregulated, such as the epithelial genes
Cdh1, Icam1, Celsr2, Krt8, and Krt80 and the mesenchymal
gene Lef1. Cross-linking-ChIP (X-ChIP) analysis on immortalizedological replicates.
qRT-PCR, normalized against the b2-microglobulin housekeeping gene and
biological replicates, each with 3 technical replicates.
2, and 16 or the percentage of CD44/CD54 cells (H) at day 9. n = 3 biological
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MEFs corroborated the binding of Mybl2 to Lef1, Tgfbr3,
Col11a1, and Col6a2 (Figure S8B). These data suggest that
Mybl2 overexpression during reprogramming alters the proper
cell fate decisions required for the MET transition that takes
place in the initiation steps of somatic reprogramming (Figures
6E, 6F, S8C, and S8D).
In conclusion, these data demonstrate that high levels of
Mybl2 during the early stages of reprogramming affect the chain
of events that are required for reprogramming to occur and thus
suggest that overexpression of Mybl2 at an early time point
blocks the reprogramming process by affecting the chromatin
landscape, thereby deregulating the expression of key genes
such as Lef1 and Cdh1 that are required for proper MET transi-
tion (Figure 7).
DISCUSSION
In this study, we found an important and as-yet uncharacter-
ized function for Mybl2 in somatic cellular reprogramming
that highlights the importance of both the timing and the levels
of Mybl2 expression. As expected, given the critical role of
Mybl2 in proliferation (Musa et al., 2017), cells that did not ex-
press Mybl2 were incapable of reprogramming. We set out to
study how an increase in the expression of Mybl2 could affect
somatic reprogramming using either a single polycistronic vec-
tor or secondary reprogramming MEFs. We found that co-
expression of Mybl2 together with Oct4, Sox2, and Klf4
profoundly impaired the efficiency of reprogramming. These re-
sults are in clear contrast to other published work in which
important genes for reprogramming have been identified, re-
sulting in opposite effects when loss-of-function and gain-of-
function experiments were performed (Banito and Gil, 2010;
Chen et al., 2013; Hanna et al., 2009; Kawamura et al., 2009;
Maekawa et al., 2011; Onder et al., 2012; Silva et al., 2009;
Unternaehrer et al., 2014).
We confirmed that the exogenous pluripotent genes were
expressed and that the cells infected with OSKB or Tg reprog-
rammable MEFs infected with Mybl2-AmCyan had not become
senescent or apoptotic, two important barriers for the reprog-
ramming process (Banito and Gil, 2010; Hong et al., 2009;
Mario´n et al., 2009; Utikal et al., 2009). Moreover, a time course
of MEFs infected with either OSKB or Tg reprogrammableFigure 5. Mybl2 Overexpression Changes the Chromatin Landscape in
(A) Schematic representation of the experimental design.
(B) Profiles of the ATAC-seq signals within each 1,000-bp window centered on ea
MEFs 4 days afterMybl2-AmCyan infection, no reprogramming (Mybl2 no dox) (n =
and 3 days after dox addition (AmCyan + dox, Mybl2-AmCyan + dox, respectively
seq tag count signal for Mybl2-treated relative to control (AmCyan).
(C) Reprogramming pioneer factor and Mybl2 motif density within each 200-bp w
Mybl2 ATAC-seq peaks.
(D) Reprogramming pioneer factor motif density in top 10% (blue) or bottom 10%
overexpressed cells at day 3 of reprogramming.
(E) Number of unique ATAC-seq peaks in control and treated cells after perform
(F) Motif enrichment analysis in unique control ATAC-seq peaks at day 3 of repro
(G) Motif enrichment analysis in Mybl2-AmCyan ATAC-seq peaks at day 3 of rep
(H) Gene Ontology (GO) analysis for the closest gene to unique ATAC-seq peaks
(I) GO analysis for the closest gene to unique ATAC-seq peaks present in Mybl2
See also Figure S7.
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of physical characteristics associated with reprogramming,
because those cells did not exhibit the expected kinetics of
CD44/CD54 expression (O’Malley et al., 2013). We also
observed that the upregulation of early and late pluripotency
genes was hampered when cells were infected with OSKB or
Tg reprogrammable MEFs infected with Mybl2-AmCyan (Fig-
ure 3), indicating that increasing Mybl2 levels unbalance the mo-
lecular events required for the early stages of reprogramming.
Different studies have shown a specific roadmap during the re-
programming process, with two waves during reprogramming
that encompass three different steps: initiation, maturation,
and stabilization (Polo et al., 2012; Samavarchi-Tehrani et al.,
2010). It has also become increasingly clear that during the initi-
ation phase, cell fate decisions change from a mesenchymal to
an epithelial program. Hence, fibroblasts downregulate mesen-
chymal-related genes to suppress the epithelial-to-mesen-
chymal transition (EMT) pathway with a concomitant activation
of the MET, upregulating the expression of epithelial genes,
with E-cadherin being one of the key genes for the establishment
of the epithelial fate (Li et al., 2010).
Suppression of the EMT during the initiation of reprogramming
requires the inhibition of transforming growth factor-b (TGF-b)
signaling by the Yamanaka factors (Li et al., 2010). Our RNA-
seq data show that Mybl2-AmCyan-transduced Tg reprogram-
mable MEFs rapidly downregulate genes (e.g., TGFbr3) that
are important for the suppression of the EMT and a rapid down-
regulation of mesenchymal genes (e.g., components of the
extracellular matrix such as the collagen family of proteins) (Li
et al., 2010; Samavarchi-Tehrani et al., 2010). Our data also
showed that overexpression of Mybl2 in Tg reprogrammable
MEFs changes the chromatin landscape of the cell, leading to
changes in open regions on genes implicated in the regulation
of the MET transition. Nonetheless, other crucial factors for the
establishment of the MET are deregulated. Thus, Mybl2-
AmCyan-transduced Tg reprogrammable MEFs are unable to
downregulate the T cell factor Lef1, which belongs to a family
of transcription factors that modulates the transcription of genes
by recruiting chromatin remodeling and histone-modifying com-
plexes to their target genes (Hoppler and Kavanagh, 2007;Merrill
et al., 2001). Lef1 has been shown to have a key role in inhibiting
the early stages of reprogramming by activating Wnt signaling.the Initiation of Reprogramming of Tg Reprogrammable MEFs
ch peak for Tg MEFs at time zero (day 0 no dox) (n = 2 biological replicates), Tg
2 biological replicates), and TgMEFs infectedwith AmCyan orMybl2-AmCyan
) (n = 3 biological replicates). Peaks are shown in the order of decreasing ATAC-
indow centered on each peak in all control ATAC-seq peaks compared to all
ATAC-seq peaks (orange) from the union of peaks between control and Mybl2
ing differential peak detection.
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Figure 7. Molecular Network for the Deregulation of Cell Fate Decision Driven by Mybl2 Overexpression during Somatic Reprogramming
(A) Schematic representation of the mechanism by which Yamanaka factors Oct4 (O), Sox2 (S), and Klf4 (K) reprogram somatic cells by opening chromatin
regions and regulating specific genes required to promote the mesenchymal-to-epithelial transition (MET).
(B) Schematic representation showing chromatin landscape changes in the presence of overexpressedMybl2. Here, regions of open chromatin are bound by AP1
transcriptions factors. This binding deregulates genes important for the crucial mesenchymal-to-epithelial transition phase occurring during somatic re-
programming.Accordingly, its loss of function increases the number of Nanog+
colonies during somatic reprograming (Ho et al., 2013);
hence, the lack of reprogramming observed whenMybl2 is over-
expressed at the same time that the OSK factors could be the
result of a failure to downregulate Lef1.
Our data also showed a failure in the upregulation of epithelial
markers that are required for the initiation of the reprogramming
process in Tg reprogrammable MEFs infected with Mybl2-
AmCyan; among these are key genes required for the MET,
such as E-cadherin (Cdh1). E-cadherin, a regulator of epithelialFigure 6. Deregulation of Genes Important for Cell Fate Decision when
(A) Scatterplot showing RNA-seq expression of all detected genes in AmCyan cont
reprogramming. Points are blue where fold change was >2 in Mybl2 or red wher
(B) Expression heatmap of significantly different genes between control and Mybl
and samples were grouped using average linkage hierarchical clustering. The de
(C) GO analysis of significantly different genes from RNA-seq analysis. The g
Visualization, and Integrated Discovery.
(D) Gene set enrichment analysis of RNA-seq genes ranked based on significanc
(E) ATAC-seq and RNA-seq University of California, Santa Cruz (UCSC) genome
reprogramming. Red ovals show differential ATAC-seq peak between both cond
(F) ATAC-seq and RNA-seq UCSC genome browser tracks for deregulated epit
conditions containing Klf4 and Sox2 motives.
See also Figure S8.
1508 Cell Reports 24, 1496–1511, August 7, 2018homeostasis (Cavallaro and Christofori, 2004), has been shown
to be required for reprogramming (Li et al., 2010) because its
downregulation by small hairpin RNAs (shRNAs) (Li et al., 2010)
or small interfering RNAs (siRNAs) (Samavarchi-Tehrani et al.,
2010) reduces the number of iPSC colonies generated, while its
overexpression enhances the generation of iPSCs (Chen et al.,
2010). We also observed changes in the chromatin landscape
surrounding the Cdh1 locus when Mybl2 was overexpressed.
Our genome-wide data showed that the overexpression of
Mybl2 during reprogramming affects the way chromatin isMybl2 Is Overexpressed in Tg Reprogrammable MEFs
rol cells versusMybl2 overexpressing Tg reprogrammableMEFs after 3 days of
e fold change was >2 in AmCyan.
2 overexpressing Tg reprogrammable MEFs at day 3 of reprogramming. Genes
ndrogram shows groups of genes that clustered together.
enes were checked for biological functions using Database for Annotation,
e and tested against Hallmark gene molecular signature database.
browser tracks for Tgfbr3, the downregulation of which is required for somatic
itions containing AP1 motives.
helial gene Cdh1. Red ovals show differential ATAC-seq peak between both
remodeled and the binding of pioneer factors to specific regions.
Thus, nearly 2,000 ATAC-seq peaks, 40% of them enriched in
Yamanaka factor motifs, were absent when Mybl2 was overex-
pressed in Tg reprogrammable MEFs. These regions were
closed in MEFs at time zero and were enriched on Sox2, Klf4,
and Oct4 motifs by day 3 in the AmCyan control. Thus, contrary
to recent reports in which OSK was found to mainly target open
chromatin sites in MEFs (Chen et al., 2016; Chronis et al., 2017),
our work supports the hypothesis that Sox2, Klf4, and Oct4 act
as pioneer factors during reprogramming, which is in agreement
with other studies (Knaupp et al., 2017; Li et al., 2017; Soufi et al.,
2012). At the same time, since we observed that OSK was not
only present in closed chromatin but also in shared, open re-
gions, both standpoints can be reconciled to hold true. More-
over, our data suggest that certain regions fail to close upon
OKSM induction because of Mybl2 overexpression and that
Mybl2 favors the binding of early immediate response genes
from the AP1 family, which is known to be reprogramming
blockers (Li et al., 2017; Liu et al., 2015); however, the direct
binding of Mybl2 to those sites during somatic reprogramming
still needs to be validated.
Overall, our data points to Mybl2 as a gatekeeper for somatic
reprogramming, the levels of which are important for maintaining
a chromatin landscape that will favor the binding of pioneer fac-
tors over reprogramming blockers. This, therefore, regulates the
switch fate that fibroblasts are subjected to during the initiation
stage; that is, the concomitant loss of their mesenchymal signa-
ture and gain of an epithelial identity.STAR+METHODS
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Chemicals, Peptides, and Recombinant Proteins
Dox hyclate SIGMA Cat# D9891
Ascorbic acid (Vitamin C) SIGMA Cat# PHR1008
LIF Millipore Cat# ESG1107
4-hydroxy Tamoxifen SIGMA Cat# H7907
GSK3 inhibitor Millipore Cat# CHIR99021
MEK 1 inhibitor Millipore Cat# PD0325901
AMPure XP beads Beckman Coulter Cat#A63882
Tagment DNA Buffer Illumina Cat#15027866
NEBNext High-Fidelity 2x PCR Master Mix New England BioLabs Cat#M0541S
Critical Commercial Assays
Senescence B-galactosidase staining kit Cell Signaling Cat#9860
In situ Cell Death Detection Kit (TUNEL) Roche Cat#000000011684795910
Lenti-X qRT-PCR Titration Kit Clontech Cat# 631235
TruSeq Stranded mRNA with Ribo-Zero human/
mouse/rat assay
Illumina Cat# 20020596
TruSeq RNA Sample Prep kit Illumina Cat#RS-122-2001
KAPA hyper Prep Kit Kapa Biosystems KK8500
KAPA Library Quantification kit Kapa Biosystems Cat#KK4824
MinElute Gel Extraction Kit QIAGEN Cat#28604
NextSeq500 High output 150 cycles Illumina Cat#FC-404-2002
NextSeq500 High output 75 cycles Illumina Cat#FC-404-2005
Deposited Data
ATAC-seq data This study GEO: GSE107577
RNA-seq data This study GEO: GSE107578
Experimental Models: Cell Lines
TNG MKOS mouse line Keisuke Kaji lab N/A
HEK293T human cell line ATCC Cat# CRL-3216, RRID:CVCL_0063
Experimental Models: Organisms/Strains
mouse B6;129S4-Pou5f1tm2(EGFP)Jae/J The Jackson Laboratory JAX:008214
Mouse B6: B-myb+/D Paloma Garcia lab N/A
Mouse B6: B-myb+/F Paloma Garcia lab N/A
Mouse B6: B-myb+/D:Oct4-GFPHm This study N/A
Mouse B6: B-myb+/F:Oct4-GFPHm This study N/A
Mouse: B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J The Jackson Laboratory JAX:008463
B-myb+/D:Oct4-GFPHm:CreERT2Hm This study N/A
(Continued on next page)
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B-myb+/F:Oct4-GFPHm:CreERT2Hm This study N/A
Mouse B6: P53+/ Jorge Cammano lab N/A
Oligonucleotides
Sox2 50 NdeI; GGT TTC TTA CAT ATG ATG TAT AAC
ATG ATG GAG ACG GAG CTG AAG
This study N/A
Sox2-E2A 30; TTT CAA CAT CGC CAG CGA GTT
TCA ACA AAG CGT AGT TAG TAC ATT GCC CAC
TAC CCA TGT GCG ACA GGG GCA GTG TGC
CGT TAA TGG CCG
This study N/A
E2A-B-Myb 50; CTT TGT TGA AAC TCG CTG GCG
ATG TTG AAA GTA ACC CCG GTC CTA TGT CTC
GGC GGA CGC GCT GCG AGG ATC TGG ATG
This study N/A
B-Myb 30 ClaI; GGT TTA TCG ATT CAG GAC AGA
ATG AGG GTC CGA GAT G
This study N/A
50B-Myb; GGT TTG GAT CCA TGT CTC GGC GGA
CGC GCT GCG AGG
This study N/A
30B-Myb2-P2A; CTC CTC CAC GTC TCC AGC
CTG CTT CAG CAG GCT GAA GTT AGT AGC
TCC GCT TCC GGA CAG AAT GAG GGT CCG
AGA TGT GTG GCT G
This study N/A
P2A-50AmCyan; AGC CTG CTG AAG CAG GCT
GGA GAC GTG GAG GAG AAC CCT GGA CCT
ATG GCT CTT TCA AAC AAG TTT ATC GGA GAT
This study N/A
TGFbr3-F; ATTTCCCCTGTGCCAATGTG This study N/A
TGFbr3-R; TGAGGGTGGGGAAGCATTTT This study N/A
COL11A1_F; AGGAGAGGAGAGAATGGG This study N/A
COL11A1_R; CGAGTGTGAAGCCCCTAAGA This study N/A
LEF1_1_F; CGGATTGGAGAACGAGGGT This study N/A
LEF1_1_R; TCAGTCTGTGGGCATCTTCA This study N/A
LEF1_2_F; CCCTTAGCAATTGTTTCACGGT This study N/A
LEF1_2_R; CCACTGGAGGTTGGCTGT This study N/A
COL6a3_F; CTATGAGCCCTGAAACCCCA This study N/A
COL6a3_R; CGGGTCTGTTTTGGGAAAGG This study N/A
GpIIb Neg_F; GATTCAGCCTTTCAGCAGCACTAC This study N/A
GpIIb Neg_R; AACTGTTTGTGGACGGAGTCACTG This study N/A
Pouf5F1(Oct4) Applied biosystems Mm00658129_gH
Klf4 Applied biosystems Mm00516104_m1
Nanog Applied biosystems Mm02384862_g1
Myc Applied biosystems Mm00487804_m1
FGF4 Applied biosystems Mm00438916_g1
Sall4 Applied biosystems Mm01240680_m1
Cbx7 Applied biosystems Mm00520006_m1
ETV5 Applied biosystems Mm00465816_m1
Mybl2 Applied biosystems Mm00485340_m1
lin28a Applied biosystems Mm00524077_m1
Thy1 Applied biosystems Mm00493682_g1
Cdh1 Applied biosystems Mm01247357_m1
Cdkn1a (P21) Applied biosystems Mm04205640_g1
Cdkn2a (P16) Applied biosystems Mm00494449_m1
Trp53 (P53) Applied biosystems Mm01731290_g1
(Continued on next page)
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Col5a1 Applied biosystems Mm00489342_m1
Col14a1 Applied biosystems Mm00805269_m1
Postn Applied biosystems Mm01284919_m1
Fn1 Applied biosystems Mm01256744_m1
Krt80 Applied biosystems Mm04209123_m1
Krt8 Applied biosystems Mm04209403_g1
Lef1 Applied biosystems Mm00550265_m1
B2 microglobulin Applied biosystems Mm00437762_m1
Recombinant DNA
pHAGE-2-EF1a-mSTEMCCA-loxP George Murphy lab
(Sommer et al., 2010)
http://www.bumc.bu.edu/kottonlab/
vectors-and-plasmids/
pHAGE-2-EF1a-mSTEMCCA George Murphy lab
(Sommer et al., 2009)
http://www.bumc.bu.edu/kottonlab/
vectors-and-plasmids/
pHAGE-2-EF1a-mOSK-Cherry-loxP George Murphy lab
(Sommer et al., 2010)
http://www.bumc.bu.edu/kottonlab/
vectors-and-plasmids/
pHAGE-2-EF1a-ZsGreen George Murphy lab http://www.bumc.bu.edu/kottonlab/
vectors-and-plasmids/
pRRL-PGK-IRES-Mybl2 This article N/A
pHAGE-2-EF1a-mOSKB This article N/A
pHAGE-2-EF1a-AmCyan This article N/A
Fu-Tet-ON-Cre-P2A-ZsGreen This article N/A
Fu-Tet-ON Addis et al., 2011 Addgene 43914
pHDM-tat1b George Murphy lab N/A
pREV George Murphy lab N/A
pHDM-VSV-G George Murphy lab N/A
pHDM-Hgpm2 George Murphy lab N/A
Software and Algorithms
Bowtie 2 Langmead and Salzberg,
2012
http://bowtie-bio.sourceforge.net/bowtie2/
index.shtml
MACS2 Martin, 2011 https://github.com/taoliu/MACS
Homer Heinz et al., 2010 http://homer.ucsd.edu/homer/motif/
Tophat v2.0.10 Trapnell et al., 2009 http://ccb.jhu.edu/software/tophat
Cufflinks v2.2.1 Trapnell et al., 2009 http://cole-trapnell-lab.github.io/cufflinks/
announcements/protocol-paper/
Cuffdiff Trapnell et al., 2009 http://cole-trapnell-lab.github.io/cufflinks/
manual/
Bedtools Quinlan and Hall, 2010 http://bedtools.readthedocs.io/en/latest/
Flowjo FLOWJO LLC https://www.flowjo.com/
Illustrator Adobe System Software
Ireland
http://www.adobe.com/cn/products/cs6/
illustrator.html
ZEN Zeiss https://www.zeiss.com/microscopy/int/
software-cameras.html
GraphPad Prism 6.0 GraphPad Software https://www.graphpad.com/
scientificsoftware/prism/
See also RNA-seq and data analysis section This study N/A
See also ATAC-seq and data analysis section This study N/A
Other
Published reprogramming ATAC-Seq and
ChIP-Seq data
Knaupp et al., 2017 GSE101905
Published reprogramming ATAC-Seq Chronis et al., 2017 GSE90892
(Continued on next page)
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Published mESC ChIP-Seq Whyte et al., 2013 GSE44286
Published reprogramming AP-1 ChIP-Seq data Liu et al., 2015 GSE50776
Published MEF ATAC-Seq and AP-1 ChIP-Seq data Vierbuchen et al., 2017 GSE83295CONTACT FOR REAGENTS AND RESOURCE SHARING
Further information and requests for reagents should be directed to and will be fulfilled by Lead contact, PalomaGarcia, at p.garcia@
bham.ac.uk.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines and primary cells
293T cells were grown in Dulbecco’s modified eagle medium (DMEM) with 1%Penicillin/Streptomycin (5000U/ml), 2mML-glutamine
(all from GIBCO) and 10% fetal bovine serum (FBS, Sigma). Referred to herein as 293T medium.
MEFs were obtained from embryos at day E12.5 and grown in DMEM with 1% Penicillin/Streptomycin (5000U/ml), 2mM L-gluta-
mine, 10%–20% FBS and 0.1mM 2-mercaptoethanol (Sigma). MEFs were used prior passage 2 for all reprogramming studies.
MEFs undergoing somatic reprogramming were grown in iPSCmedium: DMEMwith 1%Penicillin/Streptomycin (5000U/ml), 2mM
L-glutamine, 5% ESC qualified FBS (Hyclone, Fisher Scientific), 1% non-essential amino acids (GIBCO), 0.1mM 2-mercaptoethanol
and 0.01% LIF (Leukemia inhibitory factor, 106U/ml, Millipore).
Mice used for the generation of MEFs
Oct4-GFP mice (B6;129S4-Pou5f1tm2(EGFP)Jae/J, The Jackson Laboratory) were crossed with B-myb+/D and B-myb+/F mice (Garcı´a
et al., 2005), for two rounds to generate B-myb+/D:Oct4-GFPHm and B-myb+/F:Oct4-GFPHmmice. Next thesemice were crossed with
CreERT2 mice (B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J, The Jackson Laboratory) to generate B-myb+/D:Oct4-GFPHm:CreERT2Hm
and B-myb+/F:Oct4-GFPHm:CreERT2Hm mice. These were then used to set up timed matings to obtain embryos at E.12.5 with
B-mybF/D:Oct4-GFPHm:CreERT2Ht or B-myb+/D:Oct4-GFPHm:CreERT2Ht to be used for experiments. P53+/ mice were a generous
gift from Jorge Caamano, University of Birmingham. P53+/micewere crossed together to generate embryos that wereP53/.Mice
were maintained on a C57/BL6 background and genotyped by Transnetyx. All animals were maintained under an animal project
license in accordance with UK legislation.
METHOD DETAILS
Lentiviral production
The Oct4,-Sox2-Klf4-c-Myc (OSKM), Zs-Green (GFP) and Oct4-Sox2-Klf4-mCherry (OSK) lentiviral backbone plasmids and the
plasmids used for packaging the lentiviruses can be found in Table S1. The lentivirus particles used in this study were grown as pre-
viously described (Mostoslavsky et al., 2006). Virus with fluorescent reporter genes were titrated by flow cytometry using a Beckman
Coulter Cyan or BD biosciences LSRFortessa flow cytometer. Viruses without fluorescent reporter genes were titrated using a
Lenti-X qRT-PCR Titration Kit (Clontech).
Primary reprogramming
MEFs were reprogrammed using lentiviral particles containing one of four backbones (pHAGE-2-E1a-mOSKM-loxP, pHAGE-2-E1a-
mOSKM, pHAGE-2-E1a-mOSKM-Cherry-loxP or pHAGE-2-E1a-mOSKB). Reprogramming was carried out in 0.1% gelatin coated 6
well or 12 well plates with 105 or 5 3 104 MEFs per well, respectively. MEFs were transduced in the presence of 5 mg/ml polybrene
(Sigma) with 2 and 20 lentiviral particles per cell diluted in full MEFmedium one day after plating. The cells were incubated at 37C for
24 hours before the infectionswere stopped by aspiration of the lentivirus containingmedium and addition of fresh iPSCmedium. The
medium on the cells was changed every 48 hours. If colonies were to be isolated the medium was changed to ESC medium when
colonies were observed using an inverted microscope (Zeiss, Axiovert 25).
Somatic reprogramming using Tg-reprogrammable MEFs
10% MEFs containing the four reprogramming factors under dox control (Chantzoura et al., 2015) were mixed with 90% wild-type
MEFs and plated onto 0.1% gelatin coated six well plates at a cell density of 105 per well. MEFs were infected with pHAGE-2-
E1a-mybL2-Linker-HA-EF1a-Amcyan or pHAGE-2-E1a-Amcyan control virus twenty-four hours prior the addition of dox. Reprog-
ramming was initiated by addition of 300ng/ml dox hyclate (Sigma) to the culture medium. The cells were cultured in iPSC mediumCell Reports 24, 1496–1511.e1–e8, August 7, 2018 e4
with 10 mg/ml vitamin C (Sigma). The cells were given fresh mediumwith dox every 48 hours and reprogramming progress wasmoni-
tored by inverted fluorescence microscopy and analyzed by flow cytometry.
Flow cytometric analysis of reprogramming process
MEFs undergoing reprogramming were stained with anti-CD44-APC (Clone IM7) and anti-CD54-biotin (clone YN1/1.7.4) antibodies
(both from Thermofisher) diluted in 5% FBS/PBS for 15 minutes on ice. After washing cells were resuspended and incubated with
anti-streptavidin-PE-Cy7 antibody (BD Boscience) diluted in 5% FBS/PBS for 10 minutes. After three washes cells were resus-
pended in 400 mL of 5%FBS in PBS and filtered through a 50 mL Celltrics filter (Partec). The CD44 andCD54 expression was analyzed
by BD biosciences LSRFortessa flow cytometer.
Generation of pHAGE-2-EF1a-mOSKB, pHAGE-2-EF1a-AmCyan, pHAGE-2-EF1a-Mybl2-HA-P2A-EF1a-AmCyan
PCR was used to clone Sox2,Mybl2, and AmCyan from plasmid DNA with the following conditions: 30 cycles of (98C for 10 s, 60C
for 15 s, 68C for 3 minutes). Each reaction contained 10ng of plasmid DNA (pHAGE-2-E1a-mOSKM-Cherry-loxP, pMB21,
pAmCyan, respectively), 4 mL dNTPs (2.5mM each, Takara Bio Inc), 1 mL GXL polymerase (1.25U, Takara Bio Inc), 10 mL PrimeSTAR
GXL Buffer (1X, Takara Bio Inc), 0.1 mL forward primer, 0.1 mL reverse primer (key resources table) and dH2O up to 50 mL final volume.
PCRwas used to combine themodified Sox2 andMybl2 fragments, themodified AmCyan and B-myb fragments with the following
conditions: 30 cycles of (98C for 10 s, 60C for 15 s, 72C for 4minutes). The reaction contained 10ng of each purified fragment, 4 mL
dNTPs (2.5mMeach, Takara Bio Inc), 1 mLGXL polymerase (1.25U, Takara Bio Inc), 10 mL PrimeSTARGXLBuffer (1X, Takara Bio Inc),
0.1 mL Sox2 50-NdeI primer, 0.1 mL b-myb 30 ClaI primer and dH2O up to 50 mL final volume.
PCR was also used to clone a gateway cassette into the pHAGE-2-EF1a-ZsGreen-W lentiviral backbone in place of the ZsGreen
genewith the following conditions: 35 cycles of (98C for 10 s, 55C for 5 s, 72C for 9 s). Each reaction contained 200ng plasmid DNA
(pMX-GW), 25 mL PrimeStarMax polymerase premix (2X, Takara Bio Inc), 0.1 mL forward primer. 0.1 mL reverse primer and dH2O up to
50 mL final volume.
Cloning products were separated by gel electrophoresis on 1%agarose gels, excised from the geland purified using aQIAGENGel
extraction Kit.
Generation of Fu-TetO-Cre-P2A-ZsGreen
PCRwas used to cloneNLS-Cre,P2A, and ZsGreen fromplasmid DNAwith the following conditions: 35 cycles of (98C for 10 s, 60C
for 15 s, 72C for 15 minutes). Each reaction contained 100ng of plasmid DNA (pHAGE-2-E1a-mOSKM-Cherry-loxP, pMB21,
pAmCyan, respectively), 25 mL Polymerase Master Mix (PrimeStar, Takara), 0.2 mM forward primer, 0.2 mM reverse primer (key re-
sources table) and dH2O up to 50 mL final volume.
PCR was used to combine the NLS-Cre, P2A, and ZsGreen fragments with the following conditions: 30 cycles of (98C for 10 s,
59C for 15 s, 72C for 4 minutes). The reaction contained 50ng of each purified fragment, 25 mL Polymerase Master Mix (PrimeStar,
Takara), 0.2 mM forward primer, 0.2 mM reverse primer containing 15bp overlapping the pENTRY2B2 vector (key resources table) and
dH2O up to 50 mL final volume.
Gibson Assembly
Gibson assembly was used to combine the gateway cassette fragment cloned from the pMX-GW plasmid into pHAGE-2-EF1a
plasmid linearized with NcoI and BamHI restriction enzymes. Gibson assembly reaction contents: 150ng insert (GW cassette),
50ng linearized vector (pHAGE-2-EF1a plasmid cut with NcoI and BamHI), 10 mL Gibson master mix (2X, NEB) and dH2O up to
20 mL final volume. The reaction was incubated at 50C for 1 hour. The reaction mixture was diluted 1:4 with dH20 and then 2 mL
was used to transform OneShot Ccdb resistant competent bacteria (Invitrogen). Gibson assembly was also used to subclone the
NLS-Cre-P2A-ZsGreen fragment into the pENTRY vector (linearized with BamHI and NotI).
Gateway cloning
Gateway cloning was used to move genes of interest from attL entry vectors to the generated attR destination vector, pHAGE-2-
EF1a-GW or Fu-TetOn (Addis et al., 2011) vector. 150ng of entry vector and 150ng of destination vector were diluted with TE buffer
to a final volume of 8 ml. 2 mL of LRClonase II enzymemix (5x, Invitrogen) was added to the sample. The DNA and enzymemixture was
incubated for 1 hour at 25C. 1 mL of Proteinase K (Invitrogen) was added and the sample was mixed and then incubated at 37C for
10 minutes. 1 mL of the reaction was transformed into competent bacteria. Any DNA that was cloned by PCR was sequenced to
confirm lack of mutations.
Cell Sorting
Cells were sorted after viral transduction or transfection by FACS on a MoFlo XDP high speed cell sorter (Beckman Coulter). Cells
were sorted for positive expression of the fluorescent reporter protein after gating for live cells and singlets.e5 Cell Reports 24, 1496–1511.e1–e8, August 7, 2018
Quantitative RT-PCR determination of mRNA levels
Real time PCRwas carried out using TaqMan PCR reaction buffer (Applied Biosystems). The reaction was carried out in a Stratagene
Mx3000P machine. At least two separate reactions with three replicates per sample were run. Relative gene expression was calcu-
lated as 2-DDCt values with b2 microglobulin as a control. Primer sequences can be obtained from the key resources table.
AP staining
AP staining was performed according to standard protocols. In brief, medium was aspirated from the well before washing with cold
PBS. The cells were fixed in 500ml cold neutral formalin buffer (0.1M Na2HPO4, 25mM Na2HPO4.H2O, 4% Paraformaldehyde) for
15 minutes. The fixative was removed and the cells were rinsed once with cold dH2O, and then left in dH2O for 15 minutes. The
dH2O was removed and 500ml of staining solution (0.1mM Naphthol AS-MX phosphate, 27.3mM N,N-Dimethylformamide (DMF),
0.7mMFast Red Violet LB Salt, 0.1M Tris-HCl pH 8.3) was added to the cells and then incubated at room temperature for 30minutes.
The staining solution was removed and the cells were washed once with dH2O and then allowed to air dry. Red positively stained
colonies were counted to assess the efficiency of reprogramming.
Senescence staining
ReprogrammedMEFs were stained for senescence by using a Senescence b-Galactosidase Staining Kit (Cell Signaling Technology)
according to the manufacturer’s instructions. The stained cells were imaged using an inverted bright field microscope at 20x magni-
fication with an attached camera.
Apoptosis staining (TUNEL)
An In SituCell Death Detection kit (TUNEL, Roche) was used to assesswhether the viral transduction ofMEFswas causing apoptosis.
MEFs induced to reprogramwere grown on 0.1%gelatin coated 10mmcoverslips in 4 well plates were stained according to theman-
ufacturer’s instructions. The stained cells were counterstained using Prolong antifade reagent with DAPI (Life Technologies). Sam-
ples were analyzed on a Zeiss LSM 510 Meta confocal microscope.
ATAC-seq
To profile open chromatin, we modified the previously published ATAC-seq protocol (Buenrostro et al., 2015): Tg-reprogrammable
MEF (three independent biological replicates) were infected with lentivirus containing Mybl2HA-Amcyan or AmCyan genes. One day
later starting of reprogramming was initiated by addition of dox and 3 days after reprogramming 50,000 cells were sorted based on
AmCyan andmOrange fluorescent proteins and nuclei were isolated as follows: 50,000 cells were pelleted by centrifuging at 5003 g
and 4C for 10 min. Cells were then washed with 50 mL of cold PBS before being pelleted again as outlined above. Pellets were then
resuspended in 500 mL of Lysis buffer (10mM TrisHcl ph7.4, 10mM NaCl, 3mM MgCl2, 0.1% IGEPAL) and placed on ice for 10 min.
Finally, cells were pelleted by centrifugation at 5003 g and 4C for 10 min before the supernatant was discarded. The isolated nuclei
were then resuspended in a 50 mL reaction buffer containing 5 mL of Tn5 transposase (Illumina), 2% Digitonin (Promega) and 25 mL of
TD buffer (Nextera sample preparation kit from Illumina) and incubated at 37C for 30 minutes. The DNAwas then purified using DNA
QIAGEN MiniElute kit and eluted into 10 mL of elution buffer. For library amplification, 10 mL of DNA was combined with 2.5 mL of in-
dexing primers (Nextera Customized PCRPrimer 1 and barcode Nextera PCRPrimer 2), 25 mL of NEBNextHigh-Fidelity 2x PCRMas-
ter Mix (New England Biolabs). DNA was then amplified for 8 cycles to enrich the tagmented DNA fragments. A PCR clean-up was
then performed using AMPure XP beads (Beckman Coulter), and the small fragments were then resuspended in 32.5 mL of resuspen-
sion buffer (provided in the Nextera kit). DNAwas quantified using a Qubit fluorometer (Life Technologies), and library sizes were then
determined using TapeStation (Agilent Technologies). Sequencing was performed using a NextSeq 500 to obtain an average of
40 million reads per sample.
Alignment of ATAC-seq data
Cutadapt (Martin, 2011) was used in paired end mode to trim the adaptor sequence and separate sequences where both read ends
were retained from sequences. Reads that aligned to the mitochondrial genome were removed in Bowtie 2 (release 2.2.5)(Langmead
and Salzberg, 2012). Bowtie 2 was then used first to align the trimmed paired-end data and then the single-ended read data to the
mm9 reference genome. ATAC-seq peaks were identified using MACS2 (Zhang et al., 2008).
Peak detection and filtering; coverage track generation
MACS v2.1.0 was used to call peaks using optional arguments:–keep-dup = auto -B–trackline -f BAMPE -g mm. bedtools was used
to filter ENCODE blacklisted sequencing regions. Bedtools and MACS bdgdiff were used to compare peak differences.
Two-way fold change analysis
Two-way fold change analyses for AmCyan and Mybl2 samples were performed as previously described for ATAC-Seq (Brignall
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Motif discovery and motif density plots
Motif discovery was performedwith the findMotifsGenome (Heinz et al., 2010) on regions top 10%or bottom 10% fold change versus
control, using default parameters. For density plots from all peaks or 10 top 10% or bottom 10% fold change versus control, the
annotatePeaks function of Homer was used with the -size 200 -hist 10 -m <motif > options and motif densities were plotted in excel.
RNA-seq
Tg- reprogrammable MEF were infected with lentivirus containing Mybl2HA-Amcyan or AmCyan genes. One day later starting of re-
programming was initiated by addition of dox and 3 days after reprogramming cells were sorted based on AmCyan and mOrange
fluorescent proteins. RNA from two independent biological replicates was extracted from cells using Triazol and cleaned using
RNeasy MinElute CleanUp kit by QIAGEN. The RNA was then quantified using a Agilent Technologies 2100 Bioanalyzer. 1 ug of total
RNA was used for the RNA-seq. RNA-seq was then carried out using the TruSeq Stranded mRNA with Ribo-Zero human/mouse/rat
assay (Illumina) following themanufacturers protocol. Samples were then paired-end sequenced using an Illumina HiSeq 2500 instru-
ment (100 plus 100 cycles, plus indices). We sequenced an average of 22 million reads per library and aligned them to the mouse
reference genome (mm10) using TopHat v2.0.10 using options: -r 100–library-type = fr-firststrand. Next, Cufflinks v2.2.1 was
used to assemble transcripts using options:–library-type = fr-firststrand. The assembled transcripts from each sample were merged
using Cuffmerge v2.2.1. Finally, Cuffdiff v2.2.1 was used to quantify differential gene expression using options:–library-type = fr-
firststrand. The complete table of differential gene expression is available at GSE107577.
Differential gene expression scatterplot was generated using metaseq 0.5.5.4 python package. Significant gene heatmap was
generated using log2 (FPKM +1) data per replicate. The heatmap was plotted using seaborn.clustermap python package.
Gene set enrichment analysis
RNA-seq expression was ranked based on fold change between control and treated samples. This ranked list was used to perform
GSEA (v3.0) using the hallmark gene set from the Molecular Signatures Database v6.1.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation were performed as previously described (Lorvellac et al., 2010). In this procedure, immortalized
MEFs infected with a Mybl2HA-Amcyan lentivirus were collected 48h post-infection for chromatin preparation using double
cross-linking. Cells were first washed with PBS and then cross-linked with Di(N-succinimidyl) glutarate (DSG) (Sigma, 8424-
500MG-F). For each assay, 2 x107 cells were suspended in 30mls PBS and incubated with 250 mL DSG (50mg/500 mlDMSO) on a
rotating wheel for 45 minutes at room temperature. After this step cells were washed 4 times with PBS and then resuspended in
10mls of PBS and used for the second cross-linking with 1% Formaldehyde for 10 minutes at room temperature. Cross-linking
was then terminated by adding 4 volumes of cold PBS+0.125 M Glycine. Following this step cells were resuspended in 300 mL of
ice-cold ChIP Lysis Buffer (50mM HEPES-KOH pH 7.5, 1mM EDTA pH 8, 1% Triton X-100, 0.1% Na Deoxycholate and proteinase
inhibitor cocktail (Roche UK, Burgess Hill, UK)), and sonicated at 4C using a Bioruptor (Diagenode, Liege, Belgium) to generate frag-
ments an average length of 400-500 bp (10 min with 30 s ‘‘ON’’ and ‘‘OFF’’ cycles, power setting high). For the immunoprecipitation,
25 mg of chromatin were diluted in 5 volumes of ChIP Dilution Buffer (1%Triton X-100, 2mMEDTA pH8, 150mMNaCl, 20mMTris-HCl
pH8 and proteinase inhibitor cocktail) plus 15 mL of Protein A Agarose and 15 mL of Protein G Agarose and incubated for 1 hour at 4C
with rotation. After this, the mix was centrifuged for 1 min at 3500rpm at 4C and the supernatant was collected and incubated with
8 mg of Mouse IgG (sc-2025) for 2 hours at 4C with rotation. At the end of this incubation, 15 mL of Protein A Agarose and 15 mL of
Protein G Agarose were added to the mix followed by 1 hour incubation at 4Cwith rotation, after which the mix was centrifuged and
the supernatant collected. During this procedure, 8 mg of mouse HA antibody (Abcam, Ab18181) was incubated in 400 mL of ChIP
Dilution Buffer supplemented with 10 mL of Protein A Agarose and 10 mL of Protein G Agarose and incubated for 4 hours at 4C
with rotation. The anibody complexes where then washed three times with ice-cold Dilution Buffer. At this stage, 10% of the material
was separated for the INPUT control and the remaining precleared chromatin and the antibody complexes were combined and incu-
bated overnight at 4C with rotation. The day after the IPs were subjected to washes with ChIP Wash Buffers (0.1% SDS, 1% Triton
X-100, 2mM EDTA, 20mM Tris-HCl pH 8, 150 mM NaCl) containing increasing NaCl concentrations, these being 150mM, 500mM,
600mM and 750mM, followed by a final wash with 10mM Tris-HCl pH 8, 10mM EDTA. After this step, IPs were resuspended in Q2
Elution Buffer (10mMTris-HCl pH 7.5, 5mMEDTA, 5mMNa-Butirate, 50mMNaCl, 1%SDS and RNase A 1 mg/ml final) and incubated
at 68C on thermomixer at 1300rpm. At the end of this incubation, 1 mL of Proteinase K (15mg/ml, Roche) was added and IPs were
further incubated for 2 hours at 68Con thermomixer at 1300rpm. After this step, IP DNAwas purified using a standard Phenol/Cloro-
form extraction followed by Ethanol precipitation. In the case of ChIP-seq assays, IP material was subjected to library preparation
using KAPA hyper Prep Kit and run on an Illumina Hiseq 2500 sequencer.
QUANTIFICATION AND STATISTICAL ANALYSIS
All data shown are presented as mean ± SEM, all the statistical details of experiments can be found in the figure legends.
When comparing datasets, two-tailed unpaired Student’s t test was applied using GraphPad Prism software, unless indicated.e7 Cell Reports 24, 1496–1511.e1–e8, August 7, 2018
No statistical methodwas used to estimate the sample size. No specific randomization or blinding protocol was used. N indicates the
numbers of independent biological replicas per experiment unless otherwise indicated. p% 0.05 was considered statistically signif-
icant. Significance tests were performed on all samples and therefore graphs lacking p values indicate results were not statistically
significant.
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA-seq, and ATAC-seq data reported in this paper is GEO: GSE107577.Cell Reports 24, 1496–1511.e1–e8, August 7, 2018 e8
